An imperfect world: assessing safety of biological treatments in systemic lupus erythematosus. Comment on the article by Materne et al
Author:
Affiliation:
1. University of Manchester Manchester UK
2. Manchester Academic Health Science Centre Manchester UK
3. University of Manchester, Manchester Academic Health Science Centre Manchester UK
Funder
Manchester Biomedical Research Centre
Publisher
Wiley
Subject
Immunology,Rheumatology,Immunology and Allergy
Reference5 articles.
1. Comparative risks of infection with belimumab versus oral immunosuppressants in patients with non‐renal systemic lupus erythematosus. Arthritis;Materne E;Rheumatol,2023
2. Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study
3. Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)
4. U.S. Food and Drug Administration.Drug Approval Package: Benlysta (belimumab) NDA #125370.2011. URL:https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125370Orig1s000TOC.cfm
5. Risk of serious infection between belimumab and oral immunosuppressants for non‐renal systemic lupus erythematosus. Arthritis;Lee YT;Rheumatol,2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3